Moderna and Merck's mRNA cancer vaccine cuts death, recurrence by 42%
Late-stage win sets up regulatory talks and could reshape how cancer is treated - and how biotech investors value mRNA platforms.

Loading the Newsroom
Curating from trusted global sources…
120 briefings · “ep”
Late-stage win sets up regulatory talks and could reshape how cancer is treated - and how biotech investors value mRNA platforms.
A vulnerability in the code behind a large share of the web is triggering a worldwide scramble to patch, and it's a reminder that your stack's oldest dependencies can be its biggest risk.
Musk's reported stake lands alongside Laurene Powell Jobs as the $111bn Paramount-WBD merger redraws Hollywood.
The deal raises a key question: should companies cover executives' personal tax bills?
Flanagan and King extend the story beyond the prom after a 105-country No. 1 debut.
A succession crisis is forcing retiring owners to hand over cafés, farms, and guesthouses to a new generation, often for nothing.
Guardian investigation ties US-made stun guns to abuse of Palestinian detainees, putting Axon's export practices in the crosshairs.
As Chinese EV makers compress development timelines, a Japanese startup is pitching AI tools to help domestic automakers keep pace. The race is now about speed.
Former Blizzard president Mike Ybarra says Microsoft should skip a $1,200-$1,800 next-gen launch and keep PS5 Pro and Series X until prices normalize.
Meta's new $150B share class gives Zuckerberg $20B in liquidity to cover the tax, but only if he stays put.
The social media giant's ad engine and AI bet absorbed a massive teen-safety settlement and a new $25B privacy fine, keeping growth on track.
The automaker is using artificial intelligence to compress product development and answer fast-moving Chinese rivals.